HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Palliative gastrectomy for advanced gastric cancer.

AbstractBACKGROUND/AIMS:
Although palliative gastrectomy for advanced gastric cancer may be favorable in selected patients presenting with bleeding and obstruction, little has been reported about the clinical significance of palliative gastrectomy, including prognosis.
METHODOLOGY:
A retrospective comparison between 84 patients with palliative gastrectomy (PG group) and 100 patients with unresectable operation (UO group) for advanced gastric cancer was carried out.
RESULTS:
The incidence of serosal invasion, peritoneal dissemination, hepatic and lymph node metastases, and undifferentiated tissue type in the UO group were significantly higher than in the PG group. Median survival after operation in the PG group (20.6 months) was significantly longer than in the UO group (5.7 months). Also, in stage IVb patients, median survival time in the PG group (10.2 months) was significantly longer than in the UO group (5.0 months). However, median survival in the patients with synchronous liver metastasis between PG (8.4 months) and UO (4.6 months) groups was not significantly different. Survival rates after operation of 6 months, 1 year and 2 years in all patients between the palliative gastrectomy group versus UO group were 83.6% versus 38.3% (P < 0.01), 63.0% versus 9.3% (P < 0.01) and 35.2% versus 0% (P < 0.01), respectively.
CONCLUSIONS:
Palliative gastrectomy compared to unresectable operation may be effective for improvement of prognosis even if stage IVb patients with peritoneal dissemination and/or distant lymph node metastasis. However, it may be unfavorable on survival of patients with synchronous liver metastasis.
AuthorsK Hanazaki, H Sodeyama, Y Mochizuki, J Igarashi, S Yokoyama, Y Sode, M Wakabayashi, N Kawamura, T Miyazaki
JournalHepato-gastroenterology (Hepatogastroenterology) 2001 Jan-Feb Vol. 48 Issue 37 Pg. 285-9 ISSN: 0172-6390 [Print] Greece
PMID11268986 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
Topics
  • Adenocarcinoma (mortality, pathology, surgery)
  • Aged
  • Antineoplastic Agents (therapeutic use)
  • Combined Modality Therapy
  • Female
  • Gastrectomy (mortality)
  • Humans
  • Male
  • Palliative Care
  • Prognosis
  • Retrospective Studies
  • Stomach Neoplasms (mortality, pathology, surgery)
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: